Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

School Inner-City Asthma Intervention Study (SICAS-2) (SICAS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02291302
Recruitment Status : Completed
First Posted : November 14, 2014
Results First Posted : September 23, 2020
Last Update Posted : September 23, 2020
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Harvard School of Public Health
Information provided by (Responsible Party):
Wanda Phipatanakul, Boston Children's Hospital

Brief Summary:
The investigators goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren.

Condition or disease Intervention/treatment Phase
Asthma Other: integrated pest management Other: air purifier Other: No intervention (control) Not Applicable

Detailed Description:
Our proposal builds upon our established, successful school-based infrastructure to determine whether a school/classroom intervention will efficiently and effectively improve asthma morbidity by reducing these exposures. Our goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren. Our central hypothesis is that reducing classroom/school exposure to mouse allergen, mold, and particulate pollutants will decrease asthma morbidity in students with asthma. The investigators plan to test this hypothesis in an intervention study of 300 elementary students with asthma from multiple classrooms in inner-city elementary schools. Our clinical trial aims are to determine the effectiveness of a school/classroom based environmental intervention (school integrated pest management and classroom air purifying filter units within these schools) to reduce asthma morbidity. Our mechanistic aim is to test the hypothesis that effects of school/classroom-based environmental interventions on symptoms/other measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in genes) relevant to airway function and asthma. This will expand our understanding of asthma immunopathogenesis and create opportunities to identify potential novel targets for asthma therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 236 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: School Inner-City Asthma Intervention Study
Actual Study Start Date : January 2015
Actual Primary Completion Date : June 2020
Actual Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: Environmental Intervention
Active Classroom air purifiers and school integrated pest management environmental intervention
Other: integrated pest management
integrated pest management and environmental strategy

Other: air purifier
air purifiers

Placebo Comparator: Sham and Control (control)
Sham air purifiers and no school integrated pest management environmental intervention
Other: No intervention (control)
no integrated pest management and sham air purifier

Placebo Comparator: Active Air Purifier and Control
Active air purifiers and no school integrated pest management environmental intervention
Other: air purifier
air purifiers

Sham Comparator: Sham and Inegrated Pest
Sham air purifiers and active school integrated pest management
Other: integrated pest management
integrated pest management and environmental strategy




Primary Outcome Measures :
  1. Maximum Number of Days With Asthma Symptoms Within 2 Weeks [ Time Frame: up to 12 months ]

    Maximum number of

    1. Days with wheezing, tightness in the chest, or cough and/or
    2. Nights with disturbed sleep as a result of asthma and/or
    3. Days on which the child had to slow down or discontinue play activities because of asthma This is defined as a cumulative assessment from the different variables listed in the Measure Description


Secondary Outcome Measures :
  1. Health Care Utilization [ Time Frame: 12 months ]
    Total asthma-related unscheduled visits (UVs) defined as sum of unscheduled clinic visits and emergency department visits, and asthma-related overnight hospitalizations /school year


Other Outcome Measures:
  1. Lung Function [ Time Frame: 12 months ]
    FEV1; FEV1/FVC* [Secondary indices : (a) FEF25-75. (b) Bronchodilator responsiveness (% change in FEV1 post albuterol)]

  2. Degree of Exposure Reduction [ Time Frame: 12 months ]
    degree of exposure reduction and primary and secondary health outcomes

  3. School Absences [ Time Frame: 12 months ]
    Number of school days missed because of asthma/ 2 weeks

  4. Composite Asthma Severity Index [ Time Frame: 12 months ]
    Day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function, and exacerbations (defined as systemic steroids for asthma )



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • grades K-8 with asthma attending sampling/intervention schools

Exclusion Criteria:

  • moving schools

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02291302


Locations
Layout table for location information
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children's Hospital
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Harvard School of Public Health
Investigators
Layout table for investigator information
Principal Investigator: Wanda Phipatanakul, MD, MS Boston Children's Hospital
  Study Documents (Full-Text)

Documents provided by Wanda Phipatanakul, Boston Children's Hospital:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wanda Phipatanakul, Professor of Pediatrics, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT02291302    
Other Study ID Numbers: U01AI110397 ( U.S. NIH Grant/Contract )
U01AI110397 ( U.S. NIH Grant/Contract )
First Posted: November 14, 2014    Key Record Dates
Results First Posted: September 23, 2020
Last Update Posted: September 23, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases